Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI.

[1]  D. Angiolillo,et al.  Antithrombotic Management of Elderly Patients With Coronary Artery Disease. , 2021, JACC. Cardiovascular interventions.

[2]  D. Angiolillo,et al.  Ticagrelor or Clopidogrel in Elderly Patients with Myocardial Infarction: When the Choice Makes the Difference. , 2020, Circulation.

[3]  B. Lindahl,et al.  Comparison Between Ticagrelor and Clopidogrel in Elderly Patients With an Acute Coronary Syndrome , 2020, Circulation.

[4]  Y. Jang,et al.  Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. , 2020, JAMA.

[5]  M. Voskuil,et al.  Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial , 2020, The Lancet.

[6]  L. Been,et al.  Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study , 2020, Journal of the American Heart Association.

[7]  M. Price,et al.  Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score. , 2020, JACC. Cardiovascular interventions.

[8]  Samin K. Sharma,et al.  Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. , 2020, Journal of the American College of Cardiology.

[9]  P. Serruys,et al.  Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD in Elderly Patients Aged Above 75 Years: a Prespecified Analysis of the Randomized GLOBAL LEADERS Trial. , 2019, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[10]  S. James,et al.  Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms , 2019, Expert opinion on drug safety.

[11]  Samin K. Sharma,et al.  Ticagrelor with or without Aspirin in High-Risk Patients after PCI. , 2019, The New England journal of medicine.

[12]  D. Angiolillo,et al.  Tailoring P2Y12 Inhibiting Therapy in Elderly Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention , 2019, Journal of the American Heart Association.

[13]  L. Been,et al.  Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus , 2019, JACC. Basic to translational science.

[14]  W. Rottbauer,et al.  Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. , 2019, The New England journal of medicine.

[15]  D. Angiolillo,et al.  Aspirin for the primary prevention of cardiovascular disease: latest evidence , 2019, Expert review of cardiovascular therapy.

[16]  Yong Hwan Park,et al.  Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. , 2019, JAMA.

[17]  H. Okayama,et al.  Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. , 2019, JAMA.

[18]  M. Price,et al.  Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention , 2019, Circulation.

[19]  Francesca N. Delling,et al.  Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association , 2019, Circulation.

[20]  H. Pohlabeln,et al.  Efficacy and Safety of Ticagrelor in Comparison to Clopidogrel in Elderly Patients With ST‐Segment–Elevation Myocardial Infarctions , 2019, Journal of the American Heart Association.

[21]  G. Levine,et al.  ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison. , 2018, Journal of the American College of Cardiology.

[22]  F. Carreras,et al.  P2Y12 antagonists and cardiac repair post-myocardial infarction: global and regional heart function analysis and molecular assessments in pigs , 2018, Cardiovascular research.

[23]  Deepak L. Bhatt,et al.  Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention , 2018, Nature Reviews Cardiology.

[24]  S. de Servi,et al.  Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization , 2018, Circulation.

[25]  S. Pocock,et al.  Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. , 2016, American heart journal.

[26]  E. Vicaut,et al.  Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial , 2016, The Lancet.

[27]  G. Lip,et al.  Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. , 2015, European heart journal.

[28]  Peter L Duffy,et al.  Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. , 2015, Journal of the American College of Cardiology.

[29]  D. Angiolillo,et al.  Novel antiplatelet agents in acute coronary syndrome , 2015, Nature Reviews Cardiology.

[30]  P. Armstrong,et al.  Elderly Patients With Acute Coronary Syndromes Managed Without Revascularization: Insights Into the Safety of Long-Term Dual Antiplatelet Therapy With Reduced-Dose Prasugrel Versus Standard-Dose Clopidogrel , 2013, Circulation.

[31]  T. Lindahl,et al.  Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. , 2013, Journal of the American College of Cardiology.

[32]  C. Cannon,et al.  Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes: A Substudy From the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial , 2012 .

[33]  Junxiang Luo,et al.  Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON‐TIMI 38 Substudy , 2012, Journal of clinical pharmacology.

[34]  D. Angiolillo,et al.  Platelet function profiles in the elderly: Results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity , 2011, Thrombosis and Haemostasis.

[35]  T. Warner,et al.  Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel , 2011, Journal of thrombosis and haemostasis : JTH.

[36]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[37]  J. Jakubowski,et al.  In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation , 2011, Journal of thrombosis and haemostasis : JTH.

[38]  Davide Capodanno,et al.  Antithrombotic therapy in the elderly. , 2010, Journal of the American College of Cardiology.

[39]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[40]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[41]  S. Hernández-Díaz,et al.  Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. , 2001, British journal of clinical pharmacology.